Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

10 Sep 2024

• By Xu Hu

lung cancer — Fosun's ALK/ROS1 inhibitor meets primary endpoint in Phase III for ALK+ advanced NSCLC • Source: Shutterstock

Related Content

EU CHMP Opinions And MAA Updates

30 Jul 2024

Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval

19 Apr 2024

Related Companies

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Pfizer Inc.

Shouyao Holdings Beijing Co Ltd

Additional Topics

China Asia Pacific Clinical Trials Research & Development Cancer BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.